中国妇幼健康研究
中國婦幼健康研究
중국부유건강연구
CHINESE JOURNAL OF MATERNAL AND CHILD HEALTH RESEARCH
2014年
6期
974-977
,共4页
张西愿%徐小博%马向东%陈必良
張西願%徐小博%馬嚮東%陳必良
장서원%서소박%마향동%진필량
上皮性卵巢癌%血管内皮生长因子%血管内皮生长因子受体1%血管内皮生长因子2%共表达%贝伐珠单抗
上皮性卵巢癌%血管內皮生長因子%血管內皮生長因子受體1%血管內皮生長因子2%共錶達%貝伐珠單抗
상피성란소암%혈관내피생장인자%혈관내피생장인자수체1%혈관내피생장인자2%공표체%패벌주단항
epithelial ovarian cancer (EOC)%vascular endothelial growth factor (VEGF)%vascular endothelial growth factor receptor 1 (VEGFR1)%vascular endothelial growth factor receptor 2 (VEGFR2)%co-expression%Bevacizumab (Bev)
目的:研究血管内皮生长因子(VEGF)及其受体血管内皮生长因子受体1(VEGFR1)、血管内皮生长因子受体2(VEGFR2)在上皮性卵巢癌中表达及临床预后意义。方法采用SP免疫组化法检测139例不同卵巢组织VEGF及其受体VEGFR1、VEGFR2的表达及在上皮性卵巢癌组织中的共表达情况,并结合临床资料进行统计分析。结果 VEGF及其受体VEGFR1、VEGFR2在上皮性卵巢癌组织中的染色强度明显高于良性卵巢肿瘤及正常卵巢组织;并且VEGF及其受体在上皮性卵巢癌组织中的表达与临床分期、腹水量的差异均具有统计学意义(χ2=4.207,P=0.034;χ2=7.432,P=0.007);在相关分析中高表达的VEGF与VEGFR2(r=0.316,P<0.05)、VEGFR1与VEGFR2(r=0.415,P<0.05)均存在相关性;VEGF及其受体三者共高表达较非共高表达患者的5年生存率差异具有统计学意义(χ2=4.043,P=0.044)。结论高表达和共表达VEGF及其受体VEGFR1和VEGFR2的患者可能存在较差预后,并且三者共表达及高表达可作为一项指导临床应用抗肿瘤血管生成药物( Bev)靶向治疗的疗效预测分子。
目的:研究血管內皮生長因子(VEGF)及其受體血管內皮生長因子受體1(VEGFR1)、血管內皮生長因子受體2(VEGFR2)在上皮性卵巢癌中錶達及臨床預後意義。方法採用SP免疫組化法檢測139例不同卵巢組織VEGF及其受體VEGFR1、VEGFR2的錶達及在上皮性卵巢癌組織中的共錶達情況,併結閤臨床資料進行統計分析。結果 VEGF及其受體VEGFR1、VEGFR2在上皮性卵巢癌組織中的染色彊度明顯高于良性卵巢腫瘤及正常卵巢組織;併且VEGF及其受體在上皮性卵巢癌組織中的錶達與臨床分期、腹水量的差異均具有統計學意義(χ2=4.207,P=0.034;χ2=7.432,P=0.007);在相關分析中高錶達的VEGF與VEGFR2(r=0.316,P<0.05)、VEGFR1與VEGFR2(r=0.415,P<0.05)均存在相關性;VEGF及其受體三者共高錶達較非共高錶達患者的5年生存率差異具有統計學意義(χ2=4.043,P=0.044)。結論高錶達和共錶達VEGF及其受體VEGFR1和VEGFR2的患者可能存在較差預後,併且三者共錶達及高錶達可作為一項指導臨床應用抗腫瘤血管生成藥物( Bev)靶嚮治療的療效預測分子。
목적:연구혈관내피생장인자(VEGF)급기수체혈관내피생장인자수체1(VEGFR1)、혈관내피생장인자수체2(VEGFR2)재상피성란소암중표체급림상예후의의。방법채용SP면역조화법검측139례불동란소조직VEGF급기수체VEGFR1、VEGFR2적표체급재상피성란소암조직중적공표체정황,병결합림상자료진행통계분석。결과 VEGF급기수체VEGFR1、VEGFR2재상피성란소암조직중적염색강도명현고우량성란소종류급정상란소조직;병차VEGF급기수체재상피성란소암조직중적표체여림상분기、복수량적차이균구유통계학의의(χ2=4.207,P=0.034;χ2=7.432,P=0.007);재상관분석중고표체적VEGF여VEGFR2(r=0.316,P<0.05)、VEGFR1여VEGFR2(r=0.415,P<0.05)균존재상관성;VEGF급기수체삼자공고표체교비공고표체환자적5년생존솔차이구유통계학의의(χ2=4.043,P=0.044)。결론고표체화공표체VEGF급기수체VEGFR1화VEGFR2적환자가능존재교차예후,병차삼자공표체급고표체가작위일항지도림상응용항종류혈관생성약물( Bev)파향치료적료효예측분자。
Objective To evaluate the expression and prognostic significance of vascular endothelial growth factor (VEGF) and its receptor vascular endothelial growth factor receptor 1( VEGFR1) and vascular endothelial growth factor receptor 2 ( VEGFR2) in epithelial ovarian cancer ( EOC) .Methods The expression and co-expression of VEGF and its receptors ( VEGFR1 and VEGFR2 ) were detected with immunohistochemistry methods in 139 different ovarian tissues and epithelial ovarian cancer .They were analyzed combining with clinical data .Results The staining intensities of VEGF and its receptor VEGFR 1 and VEGFR2 in EOC tissue were significantly higher than those in benign ovarian tumors and normal ovary .In the correlation analysis, VEGF and VEGFR2 (r=0.316,P<0.05), VEGFR1 and VEGFR2 (r=0.415,P<0.05) were highly associated.High co-expression of VEGF and its receptors was statistically different from high non-co-expression of them in 5-year survival rate (χ2 =4.043,P=0.044).Conclusion High and co-expression of VEGF, VEGFR1 and VEGFR2 may indicate poor prognosis , and the co-expression and high expression of the three can be used as a guide to choose clinical targeted therapy of anti-angiogenesis drug ( Bev) and to predict curative effect .